Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Dapoxetine Market Opportunity: Up To 60% Of Men Interested, PPD Says

Executive Summary

Johnson & Johnson's Phase III premature ejaculation therapy dapoxetine will likely have a substantial market opportunity beyond the probable labeled indications for the drug, PPD CEO Fred Eshelman said during an investor conference Feb. 5

You may also be interested in...

J&J Antipsychotic Paliperidone ER Moves Into Phase III

Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts